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Summary
Objective: To investigate the impact of a prolonged and constant active TGF- expression by the synovial lining cells on cartilage and
ligamentous joint structures in vivo.
Design: An adenoviral vector (AdTGF-1223,225) was used for the overexpression of active TGF-1 in knee joints of C57Bl/6 mice.
Results: It was found that physiological relevant levels of active TGF-1 produced by the synovial lining layer resulted in histopathological
changes: hyperplasia of synovium and chondro-osteophyte formation at the so-called chondro-synovial junctions. No histological changes
were seen after intra-articular injection of an empty control vector (AdDL70-3) or by overexpression of latent TGF-1 (AdTGF-1). The
predominant site of TGF- production in osteoarthritis (OA) and rheumatoid arthritis (RA) is the synovial lining layer. To address the question
whether the TGF--induced changes were related to the expression site in the synovial lining, the synovial lining layer was depleted by local
treatment with liposomes encapsulating clodronate. Depletion of the lining resulted in a dramatic change of TGF-1-induced pathology:
markedly reduced chondro-osteophyte formation and increased accumulation of extracellular matrix in the synovium.
Conclusion: This study shows that overexpression of active TGF-1 in the knee joint results in OA-like changes and suggests the synovial
lining cells contribute to the chondro-osteophyte formation. © 2001 OsteoArthritis Research Society International
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Transforming growth factor- (TGF-) is a pluripotent
factor. Its main effects on cells are growth inhibition of
hematopoietic, epithelial and endothelial cells, stimulation
of chemotaxis of cells including lymphocytes, macrophages
and fibroblasts, and stimulation of extracellular matrix for-
mation by mesenchymal cells1,2. Most cells constitutively
express TGF- mRNA2. TGF- is produced in a latent form
that does not bind to TGF- receptors. Regulation of TGF-
activity occurs by activation of the latent complex, modu-
lation of synthesis by growth factors including TGF-,
scavenging of mature TGF- by 2-macroglobulin and
down-regulation of receptors3. High levels of active TGF-1
have been found in synovial fluids of osteoarthritis (OA)
and rheumatoid arthritis (RA) patients4–9. TGF- might play
a dual role in RA. On the one hand, TGF-1 is proposed to
account for most of the immunosuppressive activity in the
synovial fluid of these patients6, but on the other hand
TGF- is implicated in fibrosis of the synovium10.
We previously demonstrated that multiple intraarticular
injections using high bolus amounts of acid activated128TGF-1-induced hyperplasia of synovium and chondro-
osteophytes at the chondro-synovial junctions and at liga-
ment insertions11–13. In addition, formation of cartilage-like
tissue in ligaments and the synovial membrane was
observed. Although, with the injection protocol we could not
mimic the predominant site of TGF- production as seen in
OA and RA, immunohistological studies have shown that
the synovial membrane is one of the major sites of TGF-
1 production in human arthropaties14–18. Therefore, in
this study we used adenovirally mediated overexpression
of active TGF-1 in the joint. Adenoviral vectors have
been shown to efficiently transfect synovial cells in rabbit
and murine knee joints19–23. The adenoviral-induced
expression of TGF- was restricted to the synovial lining
and mimics the continuous TGF- exposure of joints during
arthropathies. Our data underlines the impressive potency
of TGF- to induce joint pathology: hyperplasia of the
synovium, chondro-osteophyte formation at the sites of the
chondro-synovial junctions and enhanced glycosamino-
glycan content of articular cartilage. To study whether the
cells producing TGF- play a role in the TGF--induced
pathology, we depleted the synovial lining by local treat-
ment with liposomes encapsulating clodronate24–27.
In lining-depleted joints, both adenoviral overexpression
of active TGF-1 and multiple injections of recombinant
TGF- protein resulted in extensive fibrosis and an
impressive inhibition of chondro-osteophyte formation. This
implicates that lining cells could have a major role
besides production of TGF- in directing TGF-1-induced
pathology.
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RECOMBINANT ADENOVIRUSES AND TRANSFECTION OF
SYNOVIOCYTES
Three recombinant adenoviruses were used. Two con-
tained the cDNA of the full length porcine TGF-1.
AdTGF-1 expressed the wild-type (latent) protein and
AdTGF-1223,225 contained a mutation of cystein to serine
at positions 223 and 225, resulting in production of active
protein28,29. AdDL70-3, a recombinant adenovirus lacking
an expression cassette30, was used as a control vector.
Recombinant adenovirus stocks were prepared and
characterized using established methods31. Recombinant
adenovirus stocks, in PBS, 10% glycerol, were diluted in
serum free medium and 106 to 108 pfu in a total volume of
6 l was intra-articularly injected.MULTIPLE INTRA-ARTICULAR INJECTIONS OF TGF-1
Twenty nanograms or 200 ng recombinant human
TGF-1 (Genentech Inc, San Francisco, CA, U.S.A.) dis-
solved in 6 l physiological saline, supplemented with 0.1%
ultrapure bovine serum albumin (Sigma, St Louis, MO,
U.S.A.) was injected into the joint cavity of the right knee
three times on alternating days.DEPLETION OF MACROPHAGE-LIKE LINING CELLS WITH
CLODRONATE-LADEN LIPOSOMES
Multi-lamellar liposomes encapsulating the drug clodro-
nate (dichloormethylene diphosphonate (Cl2MDP), were
prepared as described previously32. Six microliters of a
liposome suspension containing 30 g of clodronate
was injected into the knee joint space of C57Bl/6 mice.
Phagocytic cells ingest the clodronate-laden liposomes, the
membrane of the liposomes is disrupted during digestion,
the clodronate is released, and subsequently cells die
by apoptosis. Intra-articular injection of clodronate-laden
liposomes into C57Bl/6 mice produced optimal depletion of
synovial lining cells seven days after injection24.HISTOLOGY
Total knee joints were dissected, fixed in 4% formalde-
hyde and processed for histology as described pre-
viously33. Standard frontal paraffin sections (7 m) were
prepared and stained with safranin O and counterstained
with Fast green. To visualize collagen in the sections, a
Sirius red F3BA/ Fast green staining was performed on the
paraffin sections. The surface area of chondro-osteophytes
was measured using the Qwin image processing and
analysis system (Leica Imaging Systems Ltd. Cambridge,
U.K.). Four chondro-osteophytes per frontal section of a
knee joint were measured. These were located at the
chondro-synovial junctions of both the patella and the
femoral condyles. Chondro-osteophytes were measured in
three sections per knee joint in the middle part of the joint,
standardized using the growth plates.DETERMINATION OF PATELLAR CARTILAGE GLYCOSAMINOGLYCAN
CONTENT
Articular cartilage glycosaminoglycan (GAG) content is
reflected by safranin O staining intensity in histologicalsections. Staining intensity was measured using the Qwin
image processing and analysis system (Leica Imaging
Systems Ltd. Cambridge, U.K.). A modified protocol as
published by van der Kraan et al.34. was used. Red staining
intensity was measured by integral measurement of
the noncalcified layer, approximately 30–40 m in width.
Measurements were corrected for lacunae. The average
GAG content in control joints was set to 100.IMMUNOHISTOCHEMISTRY OF TGF-1
Whole murine knee joints were snap frozen in liquid
nitrogen. Sections were attached to adhesive tape35, fixed
in 4% paraformaldehyde in phosphate buffered saline
(PBS) for 10 min, and either used immediately or air-dried
and stored at −70°C in an airtight container. Sections were
rehydrated in PBS and endogenous peroxidase was
blocked by incubation in 0.5% H2O2 in PBS for 30 min with
continuous shaking. Active TGF- was detected as
described36. Briefly, after two washes in PBS, sections
were incubated overnight at 4°C, with polyclonal
chicken anti-TGF- antibodies (AB-101-NA, R&D systems,
Minneapolis, MN) diluted 1:500 in 3% BSA in PBS with 1 M
of NaCl. Sections were washed four times in PBS and
incubated for 4 h at room temperature with peroxidase
conjugated rabbit anti-chicken IgY (Jackson Immuno-
research, West Grove, PA) diluted 1:500 in PBS, 3% BSA.
After four washes in PBS, peroxidase activity was detected
by a 10-min incubation in 0.5 mg/ml 3.3′-diaminobenzidine
tetrahydrochloride (Sigma, St Louis, MO) dissolved in
0.05 M TrisHCl buffer, pH 7.6, containing 0.02% H2O2.
Finally, sections were counterstained with Mayer’s hema-
toxylin and embedded in a gelatin–glycerin solution.TGF- BIOASSAY
The patella and surrounding tissue was dissected from
murine knee joints injected intraarticularly with AdTGF-
1223,225 and incubated for 1 h in serum free medium
(DMEM). Active TGF-1 in the medium was measured
using a bioassay37. Briefly, 6×104 MLEC cells (a kind gift
from Dr D. B. Rifkin) were plated per well in a 96-well plate.
Cells were allowed to attach for 4 h at 37°C. Then medium
was replaced with 100 l activated standards or samples in
DMEM/BSA. Cells were incubated for 20 h at 37°C in a
CO2 incubator. All further steps were carried out on ice.
Cells were washed with PBS and cell lysates were pre-
pared. Luciferase in the cell lysates was measured with a
luminometer.TGF- ELISA
The ELISA is specific for active TGF-1 and TGF-2.
Soluble type II TGF- receptor (3 g/ml) was coated on a
96-well plate in 0.1 M carbonate buffer (pH 9.6) by incu-
bation of 50 l per well overnight at 4°C. The 96-well plate
was washed three times with PBS, 0.05% Tween 20 and
blocked with 1% gelatine in phosphate buffer (pH 7.4), for
1 h at 37°C. 50 l TGF- samples or TGF- standards per
well were incubated for 1 h at 37°C. Chicken anti-TGF-1
antibody (R&D systems AB-101-NA) 0.2 g/ml in 0.5%
gelatine, PBS, 0.05% Tween 20 was incubated for 1 h at
37°C. The plate was incubated with rabbit anti-chicken IgY,
biotine labeled, in 0.5% gelatine in PBS, 0.05% Tween 20,
50 l per well for 1 h at 37°C. The plate was incubated
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Peroxidase activity was detected by incubation with 8 mg
per 10 ml o-phenylenediamine in phosphate buffer pH 6.0,
with 0.3% H2O2 for 10 min. This reaction was stopped with
50 l 2.5 M H2SO4 per well. Plate was read in an ELISA
plate reader at 492 nm.ResultsADENOVIRAL VECTOR MEDIATED INTRA-ARTICULAR PRODUCTION
OF ACTIVE TGF-1
Synovial tissue specimens were taken at different time
points after virus injection and incubated for 1 h in culture
medium. Active TGF-1 in the 1-h washouts was measured
with a specific bioassay (Fig. 1). One day after injection of
107 pfu AdTGF-1223,225 the synovial washouts contained
high amounts of active TGF-1 (1150±580 pg/washout). A
gradual decline of bioactive TGF-1 production was
observed for the next 7 days to about 50% of the amount
at day one. At day 14 after virus injection the joints
still produced significant amounts of active TGF-1
(150±45 pg/washout). Immunohistochemistry showed a
distinct expression of active TGF-1 in the synovial lining
cells throughout the knee joint at 18 h after AdTGF-
1223,225 injection [Fig. 2(A)]. Three weeks after injection a
few positive cells were still found (data not shown). No cells
were stained positive for active TGF-1 in the sublining,
endothelium of blood vessels, and in cartilage. No active
TGF-1 was detected with the ELISA or immunohisto-
chemistry in AdDL70-3 injected joints (data not shown).TGF-1 INDUCED HISTOPATHOLOGICAL CHANGES IN THE MURINE
KNEE JOINT
Up to 107 pfu of control AdDL70-3 virus could be injected
into the knee joint cavity without inducing an inflammatory
response. We injected 107 pfu or less in the subsequent
TGF- studies. Injection of 106 pfu of AdTGF-1223,225
resulted in a rapid but transient influx of inflammatory cells.
Eighteen hours after injection, mononuclear cells and a few
PMNs were present in the joint cavity, and disappeared
within 48 h. The same transient influx of inflammatory cells
was seen after a single injection of 100 ng of active TGF-1
protein in the joint11.
At later time points injection of AdTGF-1223,225 resulted
in marked hyperplasia of the synovium. There was no
progression of the hyperplasia between one and three
weeks after injection [Fig. 3(A)]. Safranin O staining andSirius red staining (data not shown) showed that there was
only a small amount of extracellular matrix surrounding the
cells [Fig. 3(A)]. Synovial hyperplasia was also apparent
5 days after the last of three intraarticular injections
of TGF-1 protein at alternate days (20 ng or 200 ng)
[Fig. 3(D)]. There was an accumulation of fibroblast-like
cells along the periarticular side of the collateral ligaments
both in the AdTGF-1223,225 and TGF-1 protein injected
joints. TGF-1-induced extracellular matrix production was
evident at distinct sites between ligaments and bone in
AdTGF-1223,225 injected and in TGF- protein injected
knee joints [Fig. 3(C)]. These sites showed extensive
staining with safranin O, indicating extracellular matrix
deposition.
Glycosaminoglycan (GAG) content in patellar cartilage
was determined by detecting the safranin O staining in the
non-calcified layer with the Qwin image processing and
analysis system (Leica Imaging Systems Ltd, Cambridge,
U.K.) (Table I). Murine knee joints injected with 106 pfu of
the AdTGF-1223,225 virus showed an increase in GAG
content compared to normal knee joints of 5.7% at two
weeks after injection and 6.3% 3 weeks after injection, but
this increase was not significant. Injection of 107 pfu of the
virus did not lead to an increased GAG content 3 weeks
after injection. In comparison, triple injections of 20 ng
activated recombinant TGF- resulted in a 3.5% increased
GAG content and triple injections with 200 ng resulted in a
significant increase of 9.8%.
Chondro-osteophyte formation started 1 week after
injection of AdTGF-1223,225 at the margins of articular
cartilage [Fig. 3(A)]. From 1 to 3 weeks after injection the
surface area of the chondro-osteophytes in frontal sections
increased (Table II). Histology taken 5 days after the last of
three TGF-1 protein (20 ng) injections showed chondro-
osteophyte formation at the same location as seen 3 weeks
after injection of 106 pfu AdTGF-1223,225 [Fig. 3(C)].
Larger chondro-osteophytes were formed in joints injected
with 200 ng of active TGF-1 protein (Table III). No
histopathological changes were found three weeks after
injection of control virus AdDL70-3 (2×107 pfu) or a vector
expressing latent inactive TGF-1 (107 pfu).Fig. 1. Intraarticular production of active TGF-1 at different
time points after transfection with 107 pfu of AdTGF-1223,225,
measured with a bioassay in 1 h patella washouts.EFFECT OF MACROPHAGE-LIKE SYNOVIAL CELLS ON TGF-1
INDUCED PATHOLOGY
Lining cells were depleted to investigate the importance
of the synovial lining in the different TGF-1-induced patho-
logical events. Intraarticular injection of clodronate encap-
sulated in liposomes resulted in complete depletion of the
lining cells 7 days later24. At this time point joints were
injected with 106 or 107 pfu of AdTGF-1223,225 virus. Two
days later, the level of active TGF-1 in washouts of
synovial tissue was the same as in non-depleted joints
(Table IV). Immunohistochemistry showed that in the
clodronate treated joints, active TGF-1 expression was
restricted to cells resembling fibroblasts now lining the
synovial cavity [Fig. 2(B)]. Furthermore, the immunohisto-
chemistry showed that 3 weeks after infection the number
of positive cells was the same for the depleted and the
nondepleted knee joints (not shown).
Overexpression of TGF-1 or injection of active TGF-1
recombinant protein in synovial-lining-depleted joints
resulted in an transient influx of inflammatory cells two days
after injection, as seen in the normal joints intra-articularly
injected with AdTGF-1223,225. One week after injection the
clodronate treated joints showed synovial hyperplasia,
Osteoarthritis and Cartilage Vol. 9, No. 2 131Fig. 2. Immunohistochemistry of active TGF-1 in cryosections of murine knee joints injected with 107 pfu of AdTGF-1223,225. Sections were
counterstained with heamatoxylin. The arrows indicate the position of synovial lining, which is positive for active TGF-. (A) 18 h after
injection in a normal murine knee joint; (B) 18 h after injection in a lining-depleted knee joint. Magnification 250×. F, femur; S , joint space.accompanied by an extensive extracellular matrix depo-
sition, for both the AdTGF-1223,225 and the TGF-1 protein
injected joints [Fig. 3(B),(E)].
GAG content in the non-calcified layer of patellar carti-
lage was determined by detecting the safranin O staining
(Table I). Murine knee joints injected with 106 pfu of theAdTGF-1223,225 virus showed a significant increase of the
GAG content of 23.2% at week two and 20.7% at week
three after injection. Injection of 107 pfu resulted in a
significant increase in GAG content of 11.9% at 3 weeks
after injection. In comparison triple injections of 20 ng
active recombinant TGF- protein in clodronate treated
132 A. C. Bakker et al.: Adenoviral overexpression of TGF- in the jointFig. 3. Safranin O stained paraffin sections of murine knee joints. (A) Three weeks after injection of 106 pfu AdTGF-1223,225 in a normal knee
joint. Large arrows indicate the formation of chondro-osteophytes, small arrows indicate the thickening of the synovial lining layer. (B) Three
weeks after injection of 106 pfu AdTGF-1223,225 in a lining-depleted knee joint. (C) Three weeks after injection of 106 pfu AdTGF-1223,225
in a normal knee joint. Note the cartilage-like tissue formation between the collateral ligament and bone. (D) Five days after the last of three
injections on alternate days with 200 ng TGF-1 in a normal knee joint. (E) Five days after the last of three injections of 200 ng TGF-1 on
alternate days in a lining-depleted knee joint. Magnification 100× for (A), (B), (D) and (E), and 250× for (C). P, patella; F, femur; L, collateral
ligament; M, meniscus.knee joints resulted in an increase of 6.1% 5 days after the
last of three injections on alternate days. Triple injections of
200 ng of active recombinant protein resulted in an
increase of 13.9% 5 days after the last injection.
In the synovial-lining-depleted joints the TGF-1-induced
chondro-osteophyte formation was impaired [Fig. 3(B),Tables II and III]. In lining-depleted knee joints exposed to
lower amounts of TGF- (106 pfu or 20 ng TGF- protein)
chondro-osteophyte formation was almost completely
absent with only one out of five knee joints having
chondro-osteophytes (Table III). In lining-depleted knee
joints exposed to higher amounts of TGF- (107 pfu
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osteophytes were significantly smaller than in the
non-depleted knee joints. This suggests the synovial lining
plays a role in the TGF-1-mediated changes.Table I
Glycosaminoglycan (GAG) content of the patellar cartilage measured by automated image analysis software
Synovial
lining
Protein Adenovirus
Day 5 Week 2 Week 3
20 ng 200 ng 106 pfu 106 pfu 107 pfu
Normal 103.5±6.6 109.8±4.6* 105.7±3.8 106.3±5.7 98.6±6.0
Depleted 106.1±3.9 113.9±4.9* 123.2±10.1*† 120.7±6.2*† 111.9±3.1†
Knee joints were injected with AdTGF-223,225 or three times on alternate days with activated recombinant
protein. The relative GAG content was measured as described34. Values of the control noninjected knees were
set to 100. Values are mean±S.E.
*P<0.05 compared with the control knees.
†P<0.05 for the clodronate liposome treated knees compared with the non-treated knees, using Student t-test.
N=5.Table II
Chondro-osteophyte surface area at the chondro-synovial junctions of the femur and patella of murine knee
joints, 1–3 weeks after injection of 106 pfu AdTGF-1223,225
Time point Synovial
lining
Surface area in m2
Lateral
patella
Medial
patella
Lateral
femur
Medial
femur
1 week Normal 85±36 76±54 14±16 13±25
Depleted 0 0 0 0
2 weeks Normal 218±148 262±178 203±181 116±84
Depleted 0* 5±11 34±84 19±47
3 weeks Normal 499±179 593±164 373±198 560±324
Depleted 0* 30± 73* 18±44* 1±3*
Knee joints were obtained 1, 2 and 3 weeks after injection of 106 pfu AdTGF-1223,225. The surface area of
chondro-osteophytes at the chondro-synovial junctions of the patella and the femur [as shown in Fig. 3(A)] were
measured using the Qwin image processing and analysis system (Leica Imaging Systems Ltd). Statistics were
performed using the Mann–Whitney rank sum test. Lining-depleted knees were compared to the normal knees.
Values are mean±S.E.
*P<0.05.
N=5.Discussion
High levels of active TGF-1 have been found in synovial
fluids of OA and RA patients4–9. In this study we wanted to
mimic the relatively constant high concentration of active
TGF- in the synovial fluid in arthropathies, using a recom-
binant adenoviral vector. For the overexpression of TGF-
we used the AdTGF-223,225 vector29. In this vector two
point mutations in the TGF- cDNA, changing the Cys
codons 223 and 225 in the proregion of the TGF- precur-
sor protein in Ser codons, result in secretion of up to 74%
active TGF-28. We found that intraarticular AdTGF-
223,225 injection induced hyperplasia of the synovium and
formation of chondro-osteophytes at the chondro-synovial
junctions. Furthermore, prior treatment of the knee joint
with clodronate encapsulated in liposomes resulted in
markedly reduced chondro-osteophytes, and a dramatic
increase of extracellular matrix formation around cells in
the synovium.It has been shown that cells lining the joint space
can be efficiently transfected in vivo by recombinant
adenoviruses19–23. However, there have been reports of an
inflammatory reaction caused by the intra-articular injection
of a high amount of adenovirus (5×108)20. We found that
the adenovirus-induced inflammation, 2 days after injec-
tion, was directly related to the injected dosage (data not
shown). At a dosage of 107 pfu, the AdDL70-3 control virus
injected joints were histologically hardly distinguishable
from vehicle injected joints; there was only a mild widening
of the joint cavity, without cellinflux. In subsequent studies
we injected 107 pfu or less in the murine knee joint. When
106 or 107 pfu of the AdTGF-223,225 was injected a rapid
but transient influx of predominantly monocytes was
observed. This was probably caused by the presence of
active TGF-, because this is a chemoattractant for mono-
cytes1,2. Moreover, injection of activated recombinant
TGF- showed the same amount of joint inflammation at
these early time points.
Histology taken at one, two, and three weeks after
intra-articular injection of 106 or 107 pfu of the AdTGF-
223,225 vector showed a progressive hyperplasia in the
synovium. There was also some hyperplasia alongside the
ligaments and tendons as also seen with the multiple
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Chondro-osteophyte surface area at the chondro-synovial junctions of the femur and patella of murine knee joints
Injection Synovial
lining
Surface area in m2
Lateral
patella
Medial
patella
Lateral
femur
Medial
femur
106 pfu Normal 499±179 593±164 373±198 560±324
Depleted 0* 30±73* 18±44* 1±3*
107 pfu Normal 727±472 1264±674 351±145 268±241
Depleted 0* 357±265* 237±218 416±415
20 ng Normal 284±152 342±211 202±74 233±204
Depleted 0* 0* 18±40* 20±32
200 ng Normal 535±323 1576±609 1075±547 1160±612
Depleted 117±237 186±276* 205±210* 466±417
Knee joints were obtained 3 weeks after injection of the AdTGF-1223,225 vector, or 5 days after the last of three
intraarticular injections on alternate days with 20 or 200 ng active TGF-1 protein. The surface area of
chondro-osteophytes at the chondro-synovial junctions of the patella and the femur [as shown in Fig. 3(A)] were
measured using the Qwin image processing and analysis system (Leica Imaging Systems Ltd). Statistics were
performed using the Mann–Whitney rank sum test. Lining-depleted knees were compared with the normal knees.
Values are mean±S.E.
*P<0.05.
N=5.Table IV
Intra-articular production of active TGF-1 at day two after
transfection with AdTGF-1223,225
Synovial
lining
Pfu’s
injected
TGF-
(pg/washout)
Normal 106 241±40
107 438±14
Depleted 106 286±64
107 410±354
Active TGF- was measured in 1-h patella washouts using an
ELISA. Values are mean±S.E. N=3.injection protocol. The TGF--induced hyperplasia could be
the result of its mitogenic effect on synovial cells and
interference with the apoptotic process10. Furthermore,
TGF-1 is also chemotactic for fibroblasts1,2. Between the
collateral ligaments and bone a cartilage-like tissue was
formed near the attachment site to the femur. This was also
seen in the multiple-injection protocol [Fig. 3(C)].
In earlier studies we showed that GAG deposition in
patellar cartilage was enhanced as a result of three intra-
articular injections of TGF- on alternate days11,13. This
was confirmed in the present study. In knees injected with
106 pfu of AdTGF-223,225 the GAG content of the patellar
cartilage was enhanced 2 and 3 weeks after injection, but
was not significant. However, in knees injected with 107 pfu
of the virus, GAG content was the same as in the control
knees. This was unexpected. The reason for this discrep-
ancy between the activated protein-injected knee joints and
the virus-injected knee joints could be related to the adeno-
viral vector. It has been shown that injection of an adeno-
viral vector into murine lung leads to production of TNF-,
IL-1, and IL-6 from day one until at least day seven38. We
have shown that TNF- has an inhibitory effect on articular
cartilage GAG synthesis, IL-1 has a very strong inhibitory
effect and IL-6 slightly induces GAG synthesis39. This
indicates that adenoviral vector-induced effects could have
a negative influence on GAG content of articular cartilage.
IL-1 has been shown to be able to counteract the TGF-effect on GAG synthesis and content40; this could result in
the ‘normal GAG content’ of the transfected knee joints.
The lining cells were depleted because immunohistologi-
cal studies showed that, predominantly, the synovial mem-
brane expressed TGF-1 in human arthropathies14–18. By
depletion of the synovial membrane we were able to
determine if the cells expressing TGF-1 are important for
the intraarticular TGF-1 effects. TGF- production 2 days
after injection of 106 or 107 pfu AdTGF-223,225 in the
clodronate-treated knee joints was the same as in normal
knee joints. However, dramatic differences were found in
TGF--induced pathology. There was a profound increase
in extracellular matrix deposition in the synovium and
reduced mobility of the joints. In contrast, chondro-
osteophyte formation was impaired. This was not caused
by differences in the amount of TGF-1 expression or an
altered expression pattern in the depleted joints at later
time points, since the same results were obtained with the
repeated injection protocol of activated recombinant
TGF-1 protein. This suggests an important role of the
synovial lining cells in directing TGF-1-induced pathology
in the murine knee joint, either by production of TGF--
induced secondary factors, or possibly by virus-related
proinflammatory cytokine production by the infected cells.
The latter was further examined. Recombinant TGF- pro-
tein was injected, which led to the same impaired chondro-
osteophyte formation. This indicates that the viral-induced
proinflammatory cytokines do not have a qualitative effect
on the TGF--induced chondro-osteophyte formation.
However, at present we cannot exclude that the lipo-
some treatment had an impact on periosteal cells or other
phagocytic cell types in the sublining layer of the synovium.
Chondro-osteophytes still developed when higher amounts
of virus or recombinant protein were injected, indicating
that periosteal cells were probably not depleted by the
clodronate treatment. Application of macrophage depletion
in pathologies in which TGF- plays a role will have major
effects on all aspects of the disease, and these changes
will influence the TGF- effects. The experiments reported
here only show that in the joint, macrophage-like synovial
lining cells have a major effect on TGF--directed joint
Osteoarthritis and Cartilage Vol. 9, No. 2 135pathology. Currently we are investigating if the synovial
lining cells participate in the TGF-1-induced pathology by
releasing secondary cofactors.
In the clodronate-treated knee joints injected with
106 pfu or 107 pfu of AdTGF-223,225 the GAG content of
the patellar cartilage was significantly increased compared
with nontreated AdTGF-223,225 injected knee joints. GAG
content in the knee joints injected three times with recom-
binant TGF- protein was slightly higher in clodronate-
treated knee joints compared to normal knee joints, but was
not significant. This again points to the possible involve-
ment of adenovirus-induced inhibitory factors produced
by the synovium. It has been described that Kupffer
cell depletion, using liposomes encapsulating clodronate,
decreases adenoviral-induced proinflammatory cytokine
production in the liver41. Furthermore, clodronate treatment
of knee joints significantly reduces IL-1 production in the
collagen-induced arthritis model27. This suggests that the
increase of GAG content in clodronate treated joints can be
caused by a decrease in IL-1 poduction.
In summary, local production of TGF-1 in the synovium
leads to formation of chondro-osteophytes, synovial hyper-
plasia, and formation of cartilage-like tissue between the
collateral ligaments and bone. Clodronate treatment has no
effect on the expression pattern of TGF-, but modulates
various intra-articular TGF-1 effects. It enhances the
formation of extracellular matrix in the synovium and it
partially inhibits chondro-osteophyte formation.Acknowledgments
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